Cerveau Technologies has announced a research collaboration involving the use of its investigational PET imaging agent (MK-6240) to study Alzheimer's disease.
An international team, the Dominantly Inherited Alzheimer Network Trial Unit (DIAN-TU) at Washington University School of Medicine in St. Louis, will use the agent to track levels of the protein tau, which will help determine whether certain drugs can affect Alzheimer's pathology.
The DIAN-TU trial involves people with an inherited cause of Alzheimer's that results in disease development at a young age, usually in their 30s, 40s, or 50s. The trial unit is a public-private philanthropic research partnership launched in 2012 that aims to identify drugs that prevent or slow Alzheimer's in people who are nearly certain to develop the disease due to inherited genetic mutations.
The DIAN-TU trial is ongoing at 24 sites across seven countries and has been expanded to Argentina, Brazil, China, Colombia, Germany, Hong Kong, the Republic of Ireland, Japan, South Korea, Mexico, the Netherlands, and Poland.
